Replies to post #219733 on Biotech Values

[DewDiligence]

BMY—Someone on Twitter asked (perhaps rhetorically) why this Opdivo/Yervoy sBLA is not getting an FDA priority review. Well, the TMB assays are still being tweaked, so perhaps speeding up this review by four months wouldn't be a good idea.